T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
- 31 January 2011
- journal article
- review article
- Published by Elsevier BV in Trends in Molecular Medicine
- Vol. 17 (1), 47-55
- https://doi.org/10.1016/j.molmed.2010.09.006
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasLaboratory Investigation, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- Clinical importance of B7-H3 expression in human pancreatic cancerBritish Journal of Cancer, 2009
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009
- B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interactionEuropean Journal of Immunology, 2009
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T CellsDigestive Diseases and Sciences, 2009
- Differentiation-Induced Post-Transcriptional Control of B7-H1 in Human Trophoblast CellsPlacenta, 2009
- Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?Nature Reviews Genetics, 2008
- MicroRNA expression profiles classify human cancersNature, 2005